# Treatment relations
# Express which substances treat which disorders

relation_type: treats

relations:
  # Diabetes treatments
  - source_id: metformin
    target_id: diabetes_mellitus_type_2
    strength: strong
    evidence: "First-line therapy for T2DM per ADA guidelines"

  - source_id: insulin
    target_id: diabetes_mellitus
    strength: strong
    evidence: "Indicated for all types of diabetes"

  - source_id: insulin
    target_id: diabetes_mellitus_type_2
    strength: strong
    evidence: "Used when oral agents insufficient or contraindicated"

  - source_id: insulin
    target_id: gestational_diabetes
    strength: strong
    evidence: "Preferred treatment when oral agents insufficient"

  - source_id: glyburide
    target_id: diabetes_mellitus_type_2
    strength: moderate
    evidence: "Second-line oral agent for T2DM"

  - source_id: glipizide
    target_id: diabetes_mellitus_type_2
    strength: moderate
    evidence: "Second-line oral agent for T2DM"

  # Hypertension treatments
  - source_id: lisinopril
    target_id: hypertension
    strength: strong
    evidence: "First-line antihypertensive"

  - source_id: amlodipine
    target_id: hypertension
    strength: strong
    evidence: "First-line antihypertensive"

  - source_id: losartan
    target_id: hypertension
    strength: strong
    evidence: "First-line antihypertensive"

  - source_id: methyldopa
    target_id: hypertension
    strength: moderate
    evidence: "Preferred in pregnancy-related hypertension"

  - source_id: labetalol
    target_id: hypertension
    strength: moderate
    evidence: "Preferred in pregnancy-related hypertension"

  - source_id: labetalol
    target_id: preeclampsia
    strength: strong
    evidence: "First-line for acute blood pressure control in preeclampsia"

  - source_id: nifedipine
    target_id: hypertension
    strength: moderate
    evidence: "Calcium channel blocker; safe in pregnancy"

  # HIV treatments
  - source_id: tenofovir
    target_id: hiv_infection
    strength: strong
    evidence: "Component of first-line ART regimens"

  - source_id: dolutegravir
    target_id: hiv_infection
    strength: strong
    evidence: "Preferred integrase inhibitor in first-line ART"
